MAO-B inhibitors are especially effective in the early stages of PD, where they can provide symptomatic relief as a monotherapy while also delaying the need for LD; they are also able to delay the onset of unavoidable extrapyramidal side-effects associated with LD usage [68]. This evidence concerns the gene MAOB and Parkinson disease.